A canine serum affinity agarose gel, its preparation method, and its application in antibody purification.
By using canine serum affinity agarose gel to prepare antibodies, the problem of cross-species antibody reaction was solved, achieving efficient and low-cost antibody purification, reducing non-specific adsorption, and improving detection performance and compatibility.
Patent Information
- Application Number
- CN202611304732.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-26
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies cannot effectively solve the problem of cross-species antibody reactions, resulting in limited improvement in detection performance, serious non-specific adsorption, and existing improved solutions are costly, lack adaptability, and have unstable operating procedures.
A canine serum affinity agarose gel was prepared by covalent coupling and blocking to create a cross-adsorption purification medium with broad compatibility and high stability. The specific binding of canine serum proteins to antibodies was utilized to achieve efficient purification.
It significantly reduces non-specific antibody adsorption, improves the detection signal-to-noise ratio, reduces cross-reactivity, is suitable for batch processing of small-volume samples, is low-cost and easy to operate, and improves the standardization and reproducibility of antibody purification.
Smart Images

Figure CN123102306A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of protein purification technology, specifically relating to a canine serum affinity agarose gel, its preparation method, and its application in antibody purification. Background Technology
[0002] In the core fields of immunological detection, antibody purification, and biopharmaceuticals, the directional coupling technology of antibodies with solid-phase carriers such as agarose gels is a fundamental technology for affinity chromatography purification, immunoadsorption enrichment, and the preparation of specific antibodies. Among these technologies, covalent coupling processes, exemplified by cyanogen bromide (CNBr)-activated agarose gels, can stably immobilize protein ligands such as serum immunoglobulins on the surface of solid-phase carriers, efficiently preparing immunoadsorbents and affinity chromatography media. With its strong binding stability and wide adaptability, it has become a classic preparation process in the industry, possessing significant application value in scenarios such as removing impurities, eliminating non-specific binding, and improving the specificity of immunoassays.
[0003] In routine research and production scenarios such as multi-species cross-immunoassay and the application of xenobiotic antibodies, the Fc constant regions of antibodies from different species exhibit high structural conservation, making them highly susceptible to non-specific cross-binding reactions across species. This type of non-specific binding directly leads to increased background noise in the immunoassay system, frequent false positives, and a significant decrease in effective detection sensitivity, severely limiting the purity of antibody purification and the accuracy and reliability of immunoassay results. Therefore, cross-adsorption purification of functional antibodies using heterologous serum proteins, specifically eliminating cross-reactive heterogeneous subsets in the antibody, is a crucial step in eliminating non-specific adsorption interference and improving the signal-to-noise ratio and antibody application performance.
[0004] Currently, the industry has developed several conventional improvement schemes to address the problem of antibody non-specific cross-adsorption interference. One is the antibody high-dilution method: by performing high-dilution gradients of 1:500 to 1:2000 on the antibody, the effective concentration of the antibody in the system is reduced, thereby probabilistically reducing non-specific binding behavior. This method is simple to operate and requires no additional reagents or complex procedures, but it is a passive avoidance optimization method and cannot fundamentally eliminate the inherent cross-reactive subgroups in the antibody; it can only slightly reduce non-specific adsorption. At the same time, high-dilution directly depletes the effective titer of the antibody, resulting in extremely poor improvement effects in low-abundance target antigen detection systems, easily leading to problems such as missing detection signals and insufficient sensitivity, thus greatly limiting its application. The second is the universal protein blocking method: by adding inert non-specific proteins such as bovine serum albumin, skim milk powder, and gelatin to the immune reaction system, these proteins occupy vacant active binding sites on the surface of the solid-phase carrier, blocking the ineffective binding of the antibody to the carrier. This approach only improves the non-specific adsorption problem between the carrier and the antibody, but lacks the ability to target and eliminate cross-reactivity of heterologous proteins. It fails to address the core pain point of cross-binding between antibodies from multiple species, offering no substantial help in improving the specificity of cross-species immunoassays or reducing false positive rates, resulting in extremely poor targeted improvement. Thirdly, commercially available pre-adsorbed antibodies: Existing commercially available pre-adsorbed antibodies are pre-treated antibody products by manufacturers using standardized solid-phase antigen adsorption processes, which can mitigate cross-interference to some extent. However, commercially available pre-adsorbed antibodies are expensive and have extremely high preparation costs, making them unsuitable for large-scale scientific research and mass production scenarios. Furthermore, their fixed categories and limited compatibility combinations cannot meet the customized adsorption and purification needs of various personalized antibodies against heterologous species in scientific research, resulting in severely insufficient application flexibility and adaptability. Fourthly, the traditional serum protein-coupled gel adsorption method: Heterogeneous serum proteins are covalently coupled and immobilized on an agarose gel carrier using an EDC / NHS carbodiimide system or a CNBr cyanide bromide system to prepare a specific immunoadsorption medium. Then, affinity elimination of cross-reactive heterogeneous subsets of antibodies is achieved through column chromatography. However, the chemical coupling process lacks quantitative control standards, the coupling efficiency is uncontrollable, and the saturation state of the carrier ligand cannot be accurately determined, which easily leads to insufficient coupling or overload problems. The overall process is cumbersome and time-consuming, and the coupling and adsorption effects vary significantly between batches. The process repeatability and stability are poor, which seriously restricts the industrialization and standardization of antibody cross-adsorption purification.
[0005] In summary, existing technologies cannot fundamentally solve the problem of cross-reactivity of antibodies across species, and the improvement in detection performance is limited. There is an urgent need for a standardized, quantifiable, highly stable, low-cost, and widely adaptable antibody cross-adsorption and purification process to accurately remove cross-reactive antibodies and improve the specificity and signal-to-noise ratio of immunoassay. Summary of the Invention
[0006] The purpose of this invention is to provide a canine serum affinity agarose gel, its preparation method, and its application in antibody purification.
[0007] This invention provides a method for preparing canine serum affinity agarose gel, comprising the following steps: (1) Cleaning of agarose gel medium: Centrifuge the activated agarose gel medium with acid solution, discard the supernatant, and repeat 3 to 5 times; then centrifuge with water, clean 2 to 3 times, discard the supernatant, resuspend in water, and set aside for later use; (2) Dilution of canine serum ligands: Dilute canine serum with conjugation buffer to obtain ligand solution; (3) Covalent coupling reaction: The resuspended agarose gel medium is mixed with the ligand solution to allow serum proteins in canine serum to undergo a covalent coupling reaction with activated agarose; (4) Blocking of remaining activation sites: After the covalent coupling reaction is completed, blocking buffer is added and incubated to obtain canine serum affinity agarose gel precursor; (5) Alternate washing to remove impurities: The canine serum affinity agarose gel precursor was centrifuged and washed alternately with coupling buffer and acetate buffer, 2-3 times each time; then centrifuged and washed 2-3 times with an aqueous solution containing polysorbate nonionic surfactants; finally, it was resuspended in an aqueous solution to obtain canine serum affinity agarose gel. The sedimentation volume of the activated agarose gel medium and the ratio of serum protein in canine serum are 1 mL: 10~16 mg. The coupling buffer is a mixed aqueous solution of 0.4-0.6M NaCl and 0.05-0.2M NaHCO3, with a pH of 8.0-8.6; the blocking buffer is a 0.05-0.2M Tris-Cl aqueous solution, with a pH of 8.0-9.0; and the acetate buffer is a mixed aqueous solution of 0.4-0.6M NaCl and 0.05-0.2M HAc-NaAc, with a pH of 3.6-4.5.
[0008] The sedimentation volume refers to the volume of the lower solid layer of activated agarose gel medium after the activated agarose gel medium is placed in a liquid system, allowed to stand by gravity without external pressure until the solid and liquid phases are completely separated, and the upper clear liquid is removed. For activated agarose gel medium obtained by swelling dry powder, it refers to the volume of the solid layer of activated agarose gel medium obtained by gravity sedimentation and removal of the upper clear liquid after the dry powder has fully swollen.
[0009] Further, in step (1), the preparation method of the activated agarose gel medium includes the following steps: weighing the dry powder of agarose gel activated by cyanogen bromide, adding it to an acid solution, placing it in a centrifuge tube, stirring overnight at 0~5℃ to allow the gel to fully expand, thereby obtaining the activated agarose gel medium; or, the activated agarose gel medium is an agarose gel medium activated by N-hydroxysuccinimide; the concentration of the acid solution is 1mM, and the acid solution is selected from at least one of hydrochloric acid and sulfuric acid; the amount of water used for resuspension is the same as the sedimentation volume of the activated agarose gel medium; In step (2), the canine serum is diluted 20 times with conjugation buffer; In step (4), the ratio of the volume of the blocking buffer to the sedimentation volume of the activated agarose gel medium is 1:20; In step (5), the volume ratio of the coupling buffer to the acetate buffer is 1:1; the volume ratio of the coupling buffer to the sedimentation volume of the activated agarose gel medium is 1:30; the polysorbate nonionic surfactant is selected from at least one of polysorbate-20, polysorbate-40, polysorbate-60, and polysorbate-80; and the aqueous solution is a PBS buffer with pH = 7.0~7.4. The sedimentation volume of the activated agarose gel medium and the ratio of serum protein in canine serum are 1 mL: 12~16 mg. The coupling buffer is a mixed aqueous solution of 0.5M NaCl and 0.1M NaHCO3, pH=8.3; the blocking buffer is a 0.1M Tris-Cl aqueous solution, pH=8.5; and the acetate buffer is a mixed aqueous solution of 0.5M NaCl and 0.1M HAc-NaAc, pH=4.0.
[0010] Further, in step (3), the temperature of the covalent coupling reaction is 20~30℃ and the time is 3~5h; in step (4), the incubation conditions are incubation at 20~30℃ for 1~3h, or incubation at 0~5℃ for 12~16h; in step (5), the polysorbate nonionic surfactant is polysorbate-20 with a volume concentration of 0.03%~0.07%.
[0011] The present invention also provides canine serum affinity agarose gel prepared by the above preparation method.
[0012] The present invention also provides the use of canine serum affinity agarose gel in the preparation of reagents for cross-adsorption purification of anti-human IgG Fc antibodies.
[0013] The present invention also provides a cross-adsorption purification method for anti-human IgG Fc antibody, comprising the following steps: adding canine serum affinity agarose gel to anti-human IgG Fc antibody solution, mixing and incubating, centrifuging, and collecting the supernatant to obtain purified anti-human IgG Fc antibody.
[0014] Furthermore, the mass ratio of serum protein in the canine serum affinity agarose gel to antibody in the anti-human IgG Fc antibody solution is 2:1, and the mixing, incubation, centrifugation, and collection of supernatant are repeated 2-3 times; the mixing and incubation conditions are 20-30℃ for 1-3 hours, or 0-5℃ for 12-16 hours.
[0015] The present invention also provides purified anti-human IgG Fc antibody obtained by the cross-adsorption purification method described above.
[0016] The present invention also provides the use of purified anti-human IgG Fc antibody in the preparation of immunoassay reagents, wherein the sample to be tested by the immunoassay reagents is canine blood.
[0017] This invention provides a quantitative preparation method for canine serum affinity agarose gel medium and an antibody purification method based on this medium. The canine serum affinity agarose gel is used to purify anti-human IgG Fc antibodies, removing antibody subsets in the anti-human IgG Fc antibodies that cross-react with canine serum proteins, significantly reducing the non-specific adsorption of anti-human IgG Fc antibodies in subsequent use, so that the cross-antibody adsorption of the purified antibody to canine blood decreases by 70% to 97%.
[0018] This invention prepares canine serum affinity agarose gel using microcentrifuge tubes, which is simpler than column chromatography, eliminating the need for column packing, filtration, and specialized chromatography equipment. It is also more suitable for batch processing and customized preparation of small-volume samples. The invention uses activated agarose to covalently couple canine serum total proteins with amino groups. The coupled proteins are immobilized in a three-dimensional porous gel network. Benefiting from the porous exposure characteristics of the three-dimensional matrix and the broad ligand spectrum of canine serum total proteins (including IgG Fc and other serum protein epitopes), sufficient cross-reactive epitopes can contact the target antibody in the liquid phase. Furthermore, the invention employs a blocking-alternating washing post-gel treatment process, which effectively removes loosely bound impurities while fully blocking non-specific binding sites and maintaining the activity of the coupled proteins. This effectively prevents non-specific adsorption of antibodies by the canine serum affinity agarose gel itself during subsequent use and avoids the inactivation of coupled proteins caused by forced washing. In the antibody purification process, this invention also controls the mass ratio of canine serum protein in the canine serum affinity agarose gel to antibody in the anti-human IgG Fc antibody solution to be 2:1 during each adsorption round, and performs two adsorption rounds to ensure complete removal of cross-antibodies.
[0019] This invention significantly improves ligand immobilization efficiency and batch-to-batch consistency of canine serum affinity agarose gels by precisely controlling quantitative process parameters in gel preparation steps such as ligand coupling, residual group blocking, and gel medium washing, as well as quantitative process parameters in antibody purification steps such as antibody binding and adsorption cycles. It effectively suppresses non-specific adsorption and ligand detachment, while simultaneously achieving efficient and specific antibody separation and purification. This invention solves problems in existing technologies such as insufficient standardization of operating procedures, poor batch-to-batch reproducibility, severe non-specific adsorption, easy ligand detachment, low antibody adsorption efficiency, and high cost of commercial reagents. It effectively ensures the stability of high-performance customized pre-adsorption reagents, supports standardized batch processing of small-volume samples, and provides a reliable technical solution for efficient antibody purification.
[0020] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention.
[0021] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following embodiments. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention. Attached Figure Description
[0022] Figure 1 The OD (Oxygen Demand) is the result of co-incubating unpurified goat anti-human IgG Fc antibody and purified goat anti-human IgG Fc antibody with canine blood. 450 Absorbance. Detailed Implementation
[0023] The raw materials and equipment used in this invention are all known products, obtained by purchasing commercially available products.
[0024] Example 1: Preparation of canine serum affinity agarose gel (1) Activation of agarose gel medium: Weigh 0.15g of CNBr-activated agarose gel (CNBr-activated Sepharose 4B) dry powder, add it to 10mL of 1mM hydrochloric acid, place it in a 15mL centrifuge tube, stir overnight (12~16h) at 4℃ to allow the gel to fully expand and obtain 0.5mL of agarose gel medium (or directly use 0.5mL of NHS-activated agarose gel medium instead). (2) Cleaning of agarose gel medium: After activation, the agarose gel medium was centrifuged and cleaned with 15 mL of 1 mM hydrochloric acid (800×g, 1 min), and the supernatant was discarded. This was repeated 3 times. Then, the agarose gel medium was centrifuged and cleaned with 15 mL of ultrapure water (800×g, 1 min). This was repeated twice. The agarose gel medium was resuspended in 0.5 mL of ultrapure water for later use. (3) Dilution of canine serum ligand: Take 100 μL of canine serum (containing 6~8 mg of serum protein) and dilute it 20 times with coupling buffer (0.5 M NaCl, 0.1 M NaHCO3, pH=8.3) to obtain the ligand solution; (4) Covalent coupling reaction: The resuspended agarose gel medium and the ligand solution were quickly mixed and reacted at room temperature (25°C) for 3 hours. During the reaction, the mixture was continuously and slowly shaken on a rocker shaker to ensure that the serum proteins in the canine serum were fully covalently coupled with the activated agarose. (5) Blocking of remaining activation sites: Take the supernatant and use a spectrophotometer to detect the protein concentration. If it is <0.2mg / mL, the coupling is complete. After the coupling is complete, add 10mL of blocking buffer (0.1M Tris-Cl, pH=8.5) and incubate at room temperature (25℃) for 1h (or incubate overnight at 4℃) to block the unreacted activation groups remaining on the gel and prevent non-specific adsorption of the antibody in subsequent use, thus obtaining canine serum affinity agarose gel precursor. (6) Alternate washing to remove impurities: The canine serum affinity agarose gel precursor was centrifuged and washed twice with 15 mL of coupling buffer (0.5 M NaCl, 0.1 M NaHCO3, pH=8.3) and 15 mL of acetate buffer (0.5 M NaCl, 0.1 M HAc-NaAc, pH=4.0) in sequence (800×g, 1 min) to remove loosely bound proteins and balance the pH environment of the gel. (7) PBS equilibration and storage: Use 15 mL PBS buffer (pH=7.2, containing 0.05% (v / v) polysorbate-20 (Tween-20)) to centrifuge and wash twice (800×g, 1min), and finally add 0.5 mL PBS to resuspend, and you will get canine serum affinity agarose gel, which can be used directly for antibody purification.
[0025] Example 2: Cross-adsorption purification of anti-human IgG Fc antibody Take 20 μL of canine serum affinity agarose gel (containing 100 μg canine serum protein) and add it to 50 μL of goat anti-human IgG Fc antibody solution (containing 50 μg antibody). Incubate at room temperature (25℃) for 2 h (or incubate overnight at 4℃). Then centrifuge and collect the supernatant (S1). Add fresh canine serum affinity agarose gel and incubate under the same conditions for 2 h. Centrifuge and collect the supernatant (S2). After two rounds of adsorption, the purified anti-human IgG Fc antibody is obtained.
[0026] Experiment Example 1: Specific Adsorption Experiment 1.1 Experimental Methods Two ELISA detection systems were set up, using unpurified goat anti-human IgG Fc antibody and purified goat anti-human IgG Fc antibody as detection antibodies, respectively. Eleven different canine blood samples were used as detection matrices and incubated together. The samples were grouped as follows: undiluted mixed canine blood, canine blood 1, canine blood 2, canine blood 3, canine blood 4, canine blood 5, canine blood 6, canine blood 7, canine blood 8, canine blood 9, canine blood 10, and canine blood 11. Canine blood samples 1-11 were all diluted 4-fold. The OD of the treated canine blood was measured using an ELISA reader. 450 Absorbance was used to calculate the concentration of each sample based on the standard curve plotted using recombinant protein standards (containing human IgG Fc). The differences in specific adsorption between the two systems were compared to complete the immunoquantitative detection of recombinant protein (containing human IgG Fc fragment) in canine blood.
[0027] 1.2 Experimental Results As shown in Table 1 and Figure 1 As shown, compared with unpurified goat anti-human IgG Fc antibody, purified goat anti-human IgG Fc antibody showed a higher OD value for canine blood. 450 The absorbance decreased significantly, and the non-specific adsorption decreased by 70% to 97%.
[0028] Table 1. OD of canine blood 450 absorbance In summary, this invention uses a specific preparation process to obtain canine serum affinity agarose gel, and uses this canine serum affinity agarose gel to purify anti-human IgG Fc antibodies, removing antibody subsets in anti-human IgG Fc antibodies that cross-react with canine serum proteins, significantly reducing the non-specific adsorption of anti-human IgG Fc antibodies in subsequent use, and the cross-antibody adsorption of the purified antibody to canine blood decreased by >70%. This invention prepares canine serum affinity agarose gel using microcentrifuge tubes, which is simpler than column chromatography, eliminating the need for column packing, filtration, and specialized chromatography equipment. It is also more suitable for batch processing and customized preparation of small-volume samples. Furthermore, this invention uses activated agarose to covalently couple canine serum total proteins with amino groups. The coupled proteins are immobilized in a three-dimensional porous gel network. Benefiting from the porous exposure characteristics of the three-dimensional matrix and the broad ligand spectrum of canine serum total proteins (including IgG Fc and other serum protein epitopes), sufficient cross-reactive epitopes can reach the target antibody in the liquid phase. A blocking-alternating washing post-gel treatment process is employed to effectively remove loosely bound impurities while fully blocking non-specific binding sites and maintaining the activity of the coupled proteins. This effectively prevents non-specific adsorption of antibodies by the canine serum affinity agarose gel itself during subsequent use and avoids the inactivation of coupled proteins caused by forced washing. After blocking-alternating washing, washing with PBS containing a small amount of Tween-20 at pH 7.2 removes unbound free proteins while ensuring biological activity. In the antibody purification process, this invention controls the mass ratio of serum protein in the canine serum affinity agarose gel to antibody in the anti-human IgG Fc antibody solution to 2:1 during each adsorption round, for a total of two adsorption rounds, ensuring complete removal of cross-antibodies. This invention, through a complete set of quantified canine serum affinity agarose gel preparation and antibody purification process parameters, solves the problems of insufficient standardization of operating procedures, poor batch repeatability, severe non-specific adsorption, easy ligand detachment, low antibody adsorption efficiency, and high cost of commercial reagents in existing technologies. It provides a reliable technical solution for preparing high-performance customized pre-adsorption reagents and purifying antibodies.
Claims
1. A method for preparing canine serum affinity agarose gel, characterized in that, Includes the following steps: (1) Cleaning of agarose gel medium: Centrifuge the activated agarose gel medium with acid solution, discard the supernatant, and repeat 3 to 5 times; then centrifuge with water, clean 2 to 3 times, discard the supernatant, resuspend in water, and set aside for later use; (2) Dilution of canine serum ligands: Dilute canine serum with conjugation buffer to obtain ligand solution; (3) Covalent coupling reaction: The resuspended agarose gel medium is mixed with the ligand solution to allow serum proteins in canine serum to undergo a covalent coupling reaction with activated agarose; (4) Blocking of remaining activation sites: After the covalent coupling reaction is completed, blocking buffer is added and incubated to obtain canine serum affinity agarose gel precursor; (5) Alternate washing to remove impurities: The canine serum affinity agarose gel precursor was centrifuged and washed alternately with coupling buffer and acetate buffer, 2-3 times each time; then centrifuged and washed 2-3 times with an aqueous solution containing polysorbate nonionic surfactants; finally, it was resuspended in an aqueous solution to obtain canine serum affinity agarose gel. The sedimentation volume of the activated agarose gel medium and the ratio of serum protein in canine serum are 1 mL: 10~16 mg. The coupling buffer is a mixed aqueous solution of 0.4-0.6M NaCl and 0.05-0.2M NaHCO3, with a pH of 8.0-8.6; the blocking buffer is a 0.05-0.2M Tris-Cl aqueous solution, with a pH of 8.0-9.0; and the acetate buffer is a mixed aqueous solution of 0.4-0.6M NaCl and 0.05-0.2M HAc-NaAc, with a pH of 3.6-4.
5.
2. The preparation method according to claim 1, characterized in that, In step (1), the preparation method of the activated agarose gel medium includes the following steps: weighing the dry powder of agarose gel activated by cyanogen bromide, adding it to an acid solution, placing it in a centrifuge tube, stirring overnight at 0~5℃ to allow the gel to fully expand, thereby obtaining the activated agarose gel medium; or, the activated agarose gel medium is an agarose gel medium activated by N-hydroxysuccinimide; the concentration of the acid solution is 1mM, and the acid solution is selected from at least one of hydrochloric acid and sulfuric acid; the amount of water used for resuspension is the same as the sedimentation volume of the activated agarose gel medium; In step (2), the canine serum is diluted 20-fold with conjugation buffer; In step (4), the ratio of the volume of the blocking buffer to the sedimentation volume of the activated agarose gel medium is 1:20; In step (5), the volume ratio of the coupling buffer to the acetate buffer is 1:1; the volume ratio of the coupling buffer to the sedimentation volume of the activated agarose gel medium is 1:30; the polysorbate nonionic surfactant is selected from at least one of polysorbate-20, polysorbate-40, polysorbate-60, and polysorbate-80; and the aqueous solution is a PBS buffer with pH = 7.0~7.
4. The sedimentation volume of the activated agarose gel medium and the ratio of serum protein in canine serum are 1 mL: 12~16 mg. The coupling buffer is a mixed aqueous solution of 0.5M NaCl and 0.1M NaHCO3, pH=8.3; the blocking buffer is a 0.1M Tris-Cl aqueous solution, pH=8.5; and the acetate buffer is a mixed aqueous solution of 0.5M NaCl and 0.1M HAc-NaAc, pH=4.
0.
3. The preparation method according to any one of claims 1 to 2, characterized in that, In step (3), the temperature of the covalent coupling reaction is 20~30℃ and the time is 3~5h; in step (4), the incubation conditions are incubation at 20~30℃ for 1~3h, or incubation at 0~5℃ for 12~16h; in step (5), the polysorbate nonionic surfactant is polysorbate-20 with a volume concentration of 0.03%~0.07%.
4. The canine serum affinity agarose gel prepared by the preparation method according to any one of claims 1 to 3.
5. Use of the canine serum affinity agarose gel of claim 4 in the preparation of a reagent for the cross-adsorption purification of anti-human IgG Fc antibodies.
6. A method for cross-adsorption purification of anti-human IgG Fc antibodies, characterized in that, Add the canine serum affinity agarose gel as described in claim 4 to the anti-human IgG Fc antibody solution, mix and incubate, centrifuge, and collect the supernatant to obtain the purified anti-human IgG Fc antibody.
7. The method according to claim 6, characterized in that, Includes the following steps: The mass ratio of serum protein in the canine serum affinity agarose gel to antibody in the anti-human IgG Fc antibody solution is 2:
1. The mixing, incubation, centrifugation, and collection of supernatant are repeated 2-3 times. The mixing and incubation conditions are 20-30℃ for 1-3 hours or 0-5℃ for 12-16 hours.
8. The purified anti-human IgG Fc antibody obtained by the method according to any one of claims 6 to 7.
9. The use of the purified anti-human IgG Fc antibody according to claim 8 in the preparation of an immunoassay reagent, wherein the sample to be tested in the immunoassay reagent is canine blood.
